Quote this publication Share Print

RISPERDAL - RISPERDALORO

-
Opinions on drugs - Posted on Mar 19 2013

Reason for request

Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.

-


Clinical Benefit

Substantial

The actual benefit of RISPERDAL and RISPERDALORO in the treatment of schizophrenia remains substantial.


Clinical Added Value

moderate

Like all other antipsychotics (including typical an tipsychotics), RISPERDAL and RISPERDALORO provide a moderate improvement in actual benefit (IAB III) in the treatment of schizophrenia.


Contact Us

Évaluation des médicaments

See also